Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NRXP 
NRX Pharmaceuticals Inc (NRXP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: NRXP (3-star) is a REGULAR-BUY. BUY since 19 days. Simulated Profits (2.35%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $36.25
1 Year Target Price $36.25
| 3 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 5.56% | Avg. Invested days 29 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 75.35M USD | Price to earnings Ratio - | 1Y Target Price 36.25 |
Price to earnings Ratio - | 1Y Target Price 36.25 | ||
Volume (30-day avg) 3 | Beta 1.74 | 52 Weeks Range 1.10 - 6.01 | Updated Date 10/14/2025 |
52 Weeks Range 1.10 - 6.01 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.21 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -174.88% | Return on Equity (TTM) -682.61% |
Valuation
Trailing PE - | Forward PE 2.42 | Enterprise Value 86475770 | Price to Sales(TTM) - |
Enterprise Value 86475770 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.15 | Shares Outstanding 23769901 | Shares Floating 13611085 |
Shares Outstanding 23769901 | Shares Floating 13611085 | ||
Percent Insiders 11.55 | Percent Institutions 25.47 |
Upturn AI SWOT
NRX Pharmaceuticals Inc
Company Overview
History and Background
NRX Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of central nervous system (CNS) disorders, particularly those related to acute and chronic suicidality. The company was founded to address unmet needs in mental health.
Core Business Areas
- CNS Therapeutics Development: NRX Pharma's core business revolves around the discovery, development, and commercialization of therapies targeting CNS disorders, with a primary focus on suicidal depression and PTSD.
Leadership and Structure
Dr. Jonathan Javitt is the CEO and Chairman. The company has a board of directors and various operational departments focused on research, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- NRX-101 (D-cycloserine/lurasidone): A patented, oral, fixed-dose combination of D-cycloserine and lurasidone in Phase 2b/3 development for treatment of Acute Suicidal Ideation and Behavior (ASIB) in Bipolar Disorder. Competitors include ketamine-based therapies (e.g., Spravato by Janssen), electroconvulsive therapy (ECT), and standard antidepressants. Market share is currently negligible as the product is in clinical trials.
- NRX-100 (ketamine): An IV formulation of ketamine that has received Breakthrough Therapy designation from the FDA. It is followed by NRX-101. Competitors are other ketamine formulations and approaches to treating depression. Market share is currently negligible as the product is in clinical trials.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated, with significant investment required for research and development. There is a growing need for novel therapies to address unmet needs in mental health, especially for suicidal depression.
Positioning
NRX Pharmaceuticals positions itself as an innovator in the CNS space, focused on addressing acute and severe mental health conditions like suicidal ideation. Their competitive advantage lies in their patented formulations and potential for rapid-acting treatments.
Total Addressable Market (TAM)
The estimated TAM for depression treatments is billions of dollars annually. NRX Pharma aims to capture a significant portion of the ASIB market with its novel treatments. The total US market is likely to be around $5-10 Billion.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Breakthrough Therapy designation from FDA (NRX-100)
- Patented formulations
- Experienced leadership team
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Lack of commercialized products
- High risk of clinical trial failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new CNS indications
- Accelerated regulatory pathways (e.g., FDA fast track)
- Growing awareness of mental health issues
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
- Generic competition if patents are weak
Competitors and Market Share
Key Competitors
- JNJ
- ALKS
- LLY
Competitive Landscape
NRX Pharmaceuticals faces strong competition from larger pharmaceutical companies with established CNS franchises. Its advantage lies in its novel therapies that target unmet needs, but it must navigate regulatory hurdles and secure funding.
Growth Trajectory and Initiatives
Historical Growth: NRX Pharmaceuticalsu2019 growth has been focused on advancing its clinical pipeline, rather than generating revenue. Growth depends on the outcome of its clinical trials.
Future Projections: Future growth depends on successful clinical trial results, regulatory approvals, and commercialization strategies. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for NRX-101 and NRX-100, securing partnerships, and expanding IP portfolio.
Summary
NRX Pharmaceuticals is a clinical-stage biopharmaceutical company targeting significant unmet needs in mental health, primarily suicidal ideation. While the company has innovative products and breakthrough therapy designations, its financial stability depends on clinical trial success, regulatory approvals, and future funding. Investors should carefully evaluate the risks associated with clinical-stage biotech companies, including potential trial failures and intense competition. The stock is highly speculative at this stage but has potential for high reward.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NRX Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2017-12-04 | Co-Founder, Chief Scientist Officer, Chairman & Interim CEO Dr. Jonathan C. Javitt M.D., M.P.H. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.nrxpharma.com |
Full time employees - | Website https://www.nrxpharma.com | ||
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.